A 69-year-old woman with five chronic conditions attends for her annual review. She takes 11 regular medications. According to NICE guidance on multimorbidity, which ONE of the following is the PRIMARY purpose of individualised care planning for patients with multimorbidity?
Q112
A 72-year-old man attends with his wife who reports he has become increasingly confused over the past two weeks. He has heart failure (LVEF 40%), atrial fibrillation, COPD, type 2 diabetes, and benign prostatic hyperplasia. Current medications: digoxin 125mcg OD, bisoprolol 5mg OD, furosemide 80mg OD, ramipril 10mg OD, apixaban 5mg BD, tiotropium inhaler OD, salbutamol inhaler PRN, metformin 1g BD, sitagliptin 100mg OD, and oxybutynin 5mg TDS (started 3 weeks ago for urinary frequency). Examination: pulse 56 bpm irregular, BP 118/76 mmHg, mild peripheral oedema. Chest clear. Recent bloods: Na+ 128 mmol/L (was 138 three months ago), K+ 3.2 mmol/L, eGFR 44 ml/min/1.73m², digoxin level 2.8 mcg/L (therapeutic range 0.5-2.0). What is the most likely primary cause of his confusion?
Q113
You are developing a practice protocol for structured medication reviews in patients with multimorbidity and polypharmacy. Evidence from systematic reviews and trials examining different medication review approaches has shown variable effects on clinical outcomes. Which statement best represents the current evidence regarding the effectiveness of structured medication reviews in reducing hospital admissions and mortality in patients with multimorbidity?
Q114
A 75-year-old woman with heart failure (LVEF 35%), atrial fibrillation, CKD stage 3b (eGFR 36 ml/min/1.73m²), and type 2 diabetes attends for review. Medications: bisoprolol 10mg OD, ramipril 10mg OD, spironolactone 25mg OD, furosemide 40mg OD, apixaban 5mg BD, empagliflozin 10mg OD, and atorvastatin 20mg ON. Blood tests show: Na+ 138 mmol/L, K+ 5.8 mmol/L, eGFR 36 ml/min/1.73m², HbA1c 56 mmol/mol. She feels well with no symptoms. ECG shows atrial fibrillation, rate 68 bpm, no acute changes. What is the most appropriate immediate management?
Q115
During a practice audit of patients aged over 75 taking 10+ medications, you identify that 28% are taking a proton pump inhibitor (PPI) long-term without documented indication. You review one such patient: an 80-year-old man taking lansoprazole 30mg OD for 6 years, alongside aspirin 75mg OD, atorvastatin 80mg ON, bisoprolol 5mg OD, and ramipril 10mg OD for secondary prevention following myocardial infarction 7 years ago. He has no dyspepsia, reflux symptoms, or history of peptic ulcer disease. What is the most appropriate management of his PPI?
Q116
You are reviewing a 77-year-old man with Parkinson's disease, type 2 diabetes, hypertension, benign prostatic hyperplasia, and recurrent postural hypotension. Current medications: co-careldopa 25/100 TDS, ropinirole 8mg TDS, metformin 1g BD, linagliptin 5mg OD, amlodipine 10mg OD, doxazosin 4mg ON, tamsulosin 400mcg OD, and fludrocortisone 100mcg OD for postural hypotension. His lying BP is 156/88 mmHg, standing BP is 98/62 mmHg with dizziness. What represents the most rational approach to reducing his treatment burden while improving his symptoms?
Q117
A 68-year-old woman with atrial fibrillation, heart failure (LVEF 42%), hypertension, type 2 diabetes, and osteoarthritis is taking warfarin (target INR 2-3), bisoprolol, furosemide, ramipril, metformin, gliclazide, and co-codamol. Her INR has been unstable over the past 4 months, ranging from 1.6 to 4.2, requiring frequent monitoring. Adherence appears good. She has no symptoms of heart failure decompensation or bleeding. What medication-related factor is most likely contributing to her INR instability?
Q118
During a structured medication review using the NO TEARS tool for a 73-year-old woman with rheumatoid arthritis, hypertension, type 2 diabetes, and chronic pain, you identify that she takes: methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg BD, prednisolone 5mg OD, amlodipine 5mg OD, ramipril 5mg OD, metformin 1g BD, tramadol 50mg QDS, and paracetamol 1g QDS. She reports constipation and daytime drowsiness. Which component of the NO TEARS mnemonic is most relevant to addressing her symptoms?
Q119
A 71-year-old man with COPD (post-bronchodilator FEV1 52% predicted), type 2 diabetes, hypertension, benign prostatic hyperplasia, and depression attends for annual review. Medications: metformin 1g BD, gliclazide 80mg BD, amlodipine 10mg OD, ramipril 10mg OD, tamsulosin 400mcg OD, finasteride 5mg OD, sertraline 100mg OD, tiotropium inhaler OD, salbutamol inhaler PRN, and beclometasone/formoterol 200/6 two puffs BD. He reports two COPD exacerbations in the past year requiring oral prednisolone and antibiotics. His recent HbA1c is 72 mmol/mol. What change to his treatment regimen best addresses both his COPD exacerbations and diabetes control?
Q120
You are conducting a medication review for a 76-year-old woman with osteoarthritis, osteoporosis, gastro-oesophageal reflux disease, and recurrent urinary tract infections. She takes alendronic acid 70mg weekly, calcium/vitamin D daily, omeprazole 20mg OD, paracetamol 1g QDS, and recently completed a 7-day course of trimethoprim. She mentions she has been taking ibuprofen 400mg TDS purchased over-the-counter for the past 3 months for worsening hip pain. Recent blood tests show: Hb 102 g/L (previous 128 g/L six months ago), MCV 78 fL, ferritin 18 mcg/L, eGFR 42 ml/min/1.73m² (previous 58 ml/min/1.73m² six months ago). What is the most important immediate action?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 111: A 69-year-old woman with five chronic conditions attends for her annual review. She takes 11 regular medications. According to NICE guidance on multimorbidity, which ONE of the following is the PRIMARY purpose of individualised care planning for patients with multimorbidity?
A. To reduce overall medication burden by at least 30%
B. To prioritise treatment of the condition with highest mortality risk
C. To take into account the patient's individual needs, preferences and priorities (Correct Answer)
D. To ensure all prescribing adheres strictly to individual disease-specific guidelines
E. To identify and discontinue all medications without strong evidence base
Explanation: ***To take into account the patient's individual needs, preferences and priorities***
- According to **NICE NG56**, the core objective of individualized care planning is to customize management based on the **patient's personal goals** and values rather than just disease metrics.
- This approach facilitates **shared decision-making** to improve the patient's quality of life and reduce the **treatment burden** associated with multiple conditions.
*To reduce overall medication burden by at least 30%*
- While **polypharmacy** management is a key component, there is no specific **percentage-based target** for medication reduction in clinical guidelines.
- Focus is placed on the **appropriateness** of medications rather than achieving an arbitrary numerical reduction.
*To prioritise treatment of the condition with highest mortality risk*
- Clinical management in multimorbidity should prioritize what is **most important to the patient**, which may be **symptom control** or functional independence rather than mortality risk.
- Treating only the highest mortality risk condition ignores the **synergistic impact** of multiple chronic conditions on daily living.
*To ensure all prescribing adheres strictly to individual disease-specific guidelines*
- Strict adherence to multiple **single-disease guidelines** often leads to problematic polypharmacy and conflicting treatment recommendations.
- NICE emphasizes moving away from **specialty-based silos** toward a holistic view that considers the interaction between different treatments.
*To identify and discontinue all medications without strong evidence base*
- While **stopping ineffective treatments** is part of a medication review, the primary goal of care planning is broader than just clinical evidence evaluation.
- Some medications may lack a robust evidence base for the specific elderly multimorbid population but still provide **symptomatic relief** valued by the patient.
Question 112: A 72-year-old man attends with his wife who reports he has become increasingly confused over the past two weeks. He has heart failure (LVEF 40%), atrial fibrillation, COPD, type 2 diabetes, and benign prostatic hyperplasia. Current medications: digoxin 125mcg OD, bisoprolol 5mg OD, furosemide 80mg OD, ramipril 10mg OD, apixaban 5mg BD, tiotropium inhaler OD, salbutamol inhaler PRN, metformin 1g BD, sitagliptin 100mg OD, and oxybutynin 5mg TDS (started 3 weeks ago for urinary frequency). Examination: pulse 56 bpm irregular, BP 118/76 mmHg, mild peripheral oedema. Chest clear. Recent bloods: Na+ 128 mmol/L (was 138 three months ago), K+ 3.2 mmol/L, eGFR 44 ml/min/1.73m², digoxin level 2.8 mcg/L (therapeutic range 0.5-2.0). What is the most likely primary cause of his confusion?
A. Digoxin toxicity secondary to hypokalaemia and renal impairment
B. Hyponatraemia secondary to increased furosemide effect and SIADH from sitagliptin
C. Anticholinergic effects from oxybutynin causing delirium in an elderly patient (Correct Answer)
D. Cerebral hypoperfusion from excessive bradycardia due to digoxin and bisoprolol combination
E. Hypoglycaemia from metformin and sitagliptin combination in the context of reduced renal function
Explanation: ***Anticholinergic effects from oxybutynin causing delirium in an elderly patient*** - The initiation of **oxybutynin** three weeks ago matches the temporal onset of the patient's confusion, and it is a known high-risk medication for **anticholinergic-induced delirium** in the elderly. - Elderly patients with **polypharmacy** and clinical comorbidities like heart failure are particularly susceptible to the **cognitive burden** of anticholinergic drugs. *Digoxin toxicity secondary to hypokalaemia and renal impairment* - While the **digoxin level is elevated (2.8 mcg/L)** and exacerbated by low potassium and renal dysfunction, toxicity typically presents with gastrointestinal upset and **xanthopsia** (yellow-tinted vision) before delirium. - A heart rate of **56 bpm** in a patient taking both **bisoprolol** and digoxin is relatively stable and unlikely to be the sole driver of acute confusion. *Hyponatraemia secondary to increased furosemide effect and SIADH from sitagliptin* - A sodium level of **128 mmol/L** can cause confusion, but the acuity and temporal onset of the patient's symptoms more closely align with the introduction of the new **antimuscarinic medication**. - Hyponatremia in this patient is more likely a multifactorial issue, involving **furosemide** use and the underlying **heart failure**, rather than primarily a drug side effect like SIADH from sitagliptin being the sole cause of acute delirium. *Cerebral hypoperfusion from excessive bradycardia due to digoxin and bisoprolol combination* - The heart rate of **56 bpm** is considered mild bradycardia and is generally sufficient to maintain **cerebral perfusion** without causing acute confusion in an otherwise stable patient. - Blood pressure is **118/76 mmHg**, indicating that the patient is not in a state of clinical shock or significant systemic hypoperfusion that would typically cause acute delirium. *Hypoglycaemia from metformin and sitagliptin combination in the context of reduced renal function* - Neither **metformin** nor **sitagliptin** (a DPP-4 inhibitor) are typically associated with a high risk of **hypoglycemia** when used without insulin or sulfonylureas. - While metformin accumulation can occur in **renal impairment**, it primarily leads to **lactic acidosis** rather than acute hypoglycemia, and symptoms would differ.
Question 113: You are developing a practice protocol for structured medication reviews in patients with multimorbidity and polypharmacy. Evidence from systematic reviews and trials examining different medication review approaches has shown variable effects on clinical outcomes. Which statement best represents the current evidence regarding the effectiveness of structured medication reviews in reducing hospital admissions and mortality in patients with multimorbidity?
A. Structured medication reviews consistently reduce hospital admissions and mortality across all patient groups with multimorbidity
B. Medication reviews reduce medication-related problems and potentially inappropriate prescribing, but evidence for reducing hospital admissions and mortality is inconsistent (Correct Answer)
C. Medication reviews are effective only when conducted by clinical pharmacists, not by GPs or practice pharmacists
D. Medication reviews have no demonstrated benefit and represent an inefficient use of primary care resources
E. Medication reviews are effective only in patients taking more than 15 medications
Explanation: ***Medication reviews reduce medication-related problems and potentially inappropriate prescribing, but evidence for reducing hospital admissions and mortality is inconsistent***
- Systematic reviews consistently show that structured medication reviews are highly effective in identifying **potentially inappropriate prescribing (PIP)** and improving overall **medication appropriateness scores**.
- However, despite these benefits, large-scale trials and meta-analyses have provided **inconsistent or limited evidence** for a significant reduction in 'hard' clinical outcomes such as **hospital admissions** or **mortality** rates.
*Structured medication reviews consistently reduce hospital admissions and mortality across all patient groups with multimorbidity*
- This statement overstates the current evidence, as many robust studies have not found a consistent or statistically significant reduction in **all-cause mortality** or **hospitalization** directly attributable to medication reviews.
- The complex nature of **multimorbidity** often involves numerous non-medication-related factors that significantly influence clinical outcomes, making isolated impacts harder to demonstrate.
*Medication reviews are effective only when conducted by clinical pharmacists, not by GPs or practice pharmacists*
- Evidence supports that the effectiveness of medication reviews is largely dependent on the **structured approach** and **validated tools** used, rather than exclusively on the professional background of the reviewer.
- **GPs**, **practice pharmacists**, and **clinical pharmacists** can all effectively conduct reviews, particularly when utilizing interdisciplinary collaboration and established criteria like **STOPP/START**.
*Medication reviews have no demonstrated benefit and represent an inefficient use of primary care resources*
- This statement is incorrect as medication reviews offer clear benefits in **reducing adverse drug reactions (ADRs)**, improving **patient adherence**, and lowering **treatment burden**.
- They are considered a crucial component of **patient safety** and **quality improvement** initiatives in managing complex polypharmacy.
*Medication reviews are effective only in patients taking more than 15 medications*
- There is no specific number of medications, such as **15**, that defines the threshold for effectiveness; benefits are observed across various degrees of **polypharmacy** (often defined as ≥5 medications).
- Patients with fewer medications but who are **frail** or on **high-risk drugs** (e.g., anticoagulants, opioids) can also greatly benefit from structured medication reviews to optimize therapy and prevent harm.
Question 114: A 75-year-old woman with heart failure (LVEF 35%), atrial fibrillation, CKD stage 3b (eGFR 36 ml/min/1.73m²), and type 2 diabetes attends for review. Medications: bisoprolol 10mg OD, ramipril 10mg OD, spironolactone 25mg OD, furosemide 40mg OD, apixaban 5mg BD, empagliflozin 10mg OD, and atorvastatin 20mg ON. Blood tests show: Na+ 138 mmol/L, K+ 5.8 mmol/L, eGFR 36 ml/min/1.73m², HbA1c 56 mmol/mol. She feels well with no symptoms. ECG shows atrial fibrillation, rate 68 bpm, no acute changes. What is the most appropriate immediate management?
A. Stop spironolactone immediately and recheck potassium in 5-7 days (Correct Answer)
B. Stop empagliflozin due to declining renal function and recheck potassium in one week
C. Reduce ramipril to 5mg OD and add calcium resonium 15g TDS until potassium normalises
D. Arrange urgent same-day review for ECG monitoring and consideration of intravenous calcium gluconate
E. Continue all medications but add patiromer 8.4g OD to manage hyperkalaemia while maintaining heart failure treatment
Explanation: ***Stop spironolactone immediately and recheck potassium in 5-7 days***
- This patient has significant **hyperkalaemia (K+ 5.8 mmol/L)**. Guidelines recommend discontinuing potassium-sparing diuretics like **spironolactone** when potassium exceeds **5.5 mmol/L**, especially in the context of **CKD stage 3b**, to prevent life-threatening levels.
- **Spironolactone** is a potent contributor to hyperkalaemia. Its discontinuation is the most direct and effective immediate step to reduce potassium and is prioritized over other medications in this setting.
*Stop empagliflozin due to declining renal function and recheck potassium in one week*
- **SGLT-2 inhibitors** like empagliflozin provide crucial cardiorenal protection and are generally safe to continue as long as the **eGFR is >25 ml/min/1.73m²**, which is the case here (36 ml/min/1.73m²).
- Empagliflozin typically has a neutral or even a slightly **potassium-lowering effect**, so it is unlikely to be the primary cause of this patient's hyperkalaemia.
*Reduce ramipril to 5mg OD and add calcium resonium 15g TDS until potassium normalises*
- While **ACE inhibitors (ramipril)** contribute to hyperkalaemia, stopping the more potent potassium-sparing diuretic (spironolactone) is a more appropriate initial step in this scenario, especially for maintaining optimal heart failure therapy.
- **Calcium resonium** (sodium polystyrene sulfonate) is often poorly tolerated due to gastrointestinal side effects and is generally not the first-line outpatient management for mild-to-moderate hyperkalaemia, particularly without first adjusting causative medications.
*Arrange urgent same-day review for ECG monitoring and consideration of intravenous calcium gluconate*
- Urgent treatment with **IV calcium gluconate** is indicated for severe hyperkalaemia (typically **K+ ≥6.5 mmol/L**) or when there are **ECG changes** (e.g., peaked T-waves, QRS widening) indicating cardiac toxicity.
- The patient is **asymptomatic**, and her ECG shows **no acute changes** with a potassium level of 5.8 mmol/L, which does not warrant emergency IV treatment.
*Continue all medications but add patiromer 8.4g OD to manage hyperkalaemia while maintaining heart failure treatment*
- **Potassium binders** like patiromer are typically used for chronic hyperkalaemia management, often in a specialist setting, to enable continuation of essential RAAS inhibitors in patients with persistent hyperkalaemia.
- The immediate priority for a K+ of 5.8 mmol/L in an asymptomatic patient is to **discontinue the most prominent offending agent** (spironolactone) to ensure safety, rather than adding another medication straight away.
Question 115: During a practice audit of patients aged over 75 taking 10+ medications, you identify that 28% are taking a proton pump inhibitor (PPI) long-term without documented indication. You review one such patient: an 80-year-old man taking lansoprazole 30mg OD for 6 years, alongside aspirin 75mg OD, atorvastatin 80mg ON, bisoprolol 5mg OD, and ramipril 10mg OD for secondary prevention following myocardial infarction 7 years ago. He has no dyspepsia, reflux symptoms, or history of peptic ulcer disease. What is the most appropriate management of his PPI?
A. Continue lansoprazole indefinitely as gastroprotection for aspirin in elderly patient
B. Switch to famotidine 20mg OD to avoid long-term PPI-related risks while maintaining gastroprotection
C. Attempt to stop lansoprazole completely, warning about potential rebound dyspepsia, with trial of stopping aspirin if symptoms develop
D. Reduce lansoprazole to 15mg OD and continue long-term at this lower dose
E. Attempt to stop lansoprazole with step-down approach, restarting only if dyspepsia develops, while continuing aspirin (Correct Answer)
Explanation: ***Attempt to stop lansoprazole with step-down approach, restarting only if dyspepsia develops, while continuing aspirin***- Proper **deprescribing** is essential for patients over 75 on multiple medications when no clear indication for a **Proton Pump Inhibitor (PPI)** exists, as long-term use increases risks of **Clostridium difficile**, **osteoporosis**, and **hypomagnesaemia**.- A **step-down approach** helps manage **rebound acid hypersecretion**, which often causes transient symptoms that might otherwise be mistaken for a return of underlying disease.*Continue lansoprazole indefinitely as gastroprotection for aspirin in elderly patient*- Routine **gastroprotection** with aspirin is only indicated for high-risk patients, such as those with a history of **peptic ulcer disease**, concurrent **NSAID** use, or **anticoagulation**.- Continuing medication without a valid clinical indication contributes to **polypharmacy** and unnecessary side effect risks in the elderly.*Switch to famotidine 20mg OD to avoid long-term PPI-related risks while maintaining gastroprotection*- Switching to an **H2-receptor antagonist** does not address the core issue that acid suppression is not clinically indicated for this patient.- While it might reduce certain PPI-specific risks, it still adds to the patient's **pill burden** and carries its own side effect profile.*Attempt to stop lansoprazole completely, warning about potential rebound dyspepsia, with trial of stopping aspirin if symptoms develop*- **Aspirin** is mandatory for **secondary prevention** following a myocardial infarction; stopping it to manage acid symptoms is clinically inappropriate and increases cardiovascular risk.- Abrupt cessation without a **tapering** or step-down strategy increases the likelihood of patient failure due to severe **rebound dyspepsia**.*Reduce lansoprazole to 15mg OD and continue long-term at this lower dose*- Reducing the dose is a good first step in tapering, but maintaining it indefinitely still exposes the patient to **long-term risks** without a documented benefit.- Current guidelines emphasize **stopping** therapy entirely when there is no history of GORD or peptic ulcers requiring maintenance.
Question 116: You are reviewing a 77-year-old man with Parkinson's disease, type 2 diabetes, hypertension, benign prostatic hyperplasia, and recurrent postural hypotension. Current medications: co-careldopa 25/100 TDS, ropinirole 8mg TDS, metformin 1g BD, linagliptin 5mg OD, amlodipine 10mg OD, doxazosin 4mg ON, tamsulosin 400mcg OD, and fludrocortisone 100mcg OD for postural hypotension. His lying BP is 156/88 mmHg, standing BP is 98/62 mmHg with dizziness. What represents the most rational approach to reducing his treatment burden while improving his symptoms?
A. Stop amlodipine and increase fludrocortisone to 200mcg OD to better manage postural hypotension
B. Stop doxazosin, continue tamsulosin alone, review need for amlodipine, and consider reducing dopaminergic medication if possible (Correct Answer)
C. Stop both doxazosin and tamsulosin, as combination therapy is causing excessive hypotension
D. Add midodrine 2.5mg TDS to improve postural hypotension while continuing current antihypertensives
E. Stop fludrocortisone as it is ineffective, and add compression stockings as non-pharmacological management
Explanation: ***Stop doxazosin, continue tamsulosin alone, review need for amlodipine, and consider reducing dopaminergic medication if possible***
- **Doxazosin** is a non-selective **alpha-blocker** that significantly contributes to **postural hypotension**; using it alongside **tamsulosin** (a selective alpha-1A blocker) for BPH represents unnecessary **polypharmacy** and a major contributor to symptoms.
- Managing symptomatic **orthostatic hypotension** takes priority over treating asymptomatic **supine hypertension** in Parkinson's disease, necessitating a review of **amlodipine** and potential reduction of **dopaminergic agents** like co-careldopa and ropinirole which can exacerbate hypotension.
*Stop amlodipine and increase fludrocortisone to 200mcg OD to better manage postural hypotension*
- Increasing **fludrocortisone** without addressing other major causes of hypotension like doxazosin and dopaminergics increases the risk of **supine hypertension** and fluid overload.
- This approach adds to the **treatment burden** rather than reducing it through rational **deprescribing** of offending agents.
*Stop both doxazosin and tamsulosin, as combination therapy is causing excessive hypotension*
- Completely stopping all BPH medications (doxazosin and tamsulosin) would likely lead to a recurrence of bothersome **lower urinary tract symptoms (LUTS)** due to prostatic obstruction.
- **Tamsulosin** is uroselective and less likely than **doxazosin** to cause systemic hypotension, making it the preferred agent to retain for symptom control if BPH treatment is needed.
*Add midodrine 2.5mg TDS to improve postural hypotension while continuing current antihypertensives*
- Adding **midodrine** introduces a "prescribing cascade" where a new drug is used to treat the side effects of existing medications (**amlodipine/doxazosin/dopaminergics**).
- It fails to address the **iatrogenic** nature of the patient's symptoms and increases the complexity and pill burden of his medication regimen.
*Stop fludrocortisone as it is ineffective, and add compression stockings as non-pharmacological management*
- Stopping **fludrocortisone** abruptly in a patient with significant postural drops may lead to a worsening of **syncopal risk** if the vasodilatory medications are not addressed first.
- While **non-pharmacological** measures are helpful, they are insufficient to counteract the potent hypotensive effects of his current **polypharmacy** and do not reduce the treatment burden.
Question 117: A 68-year-old woman with atrial fibrillation, heart failure (LVEF 42%), hypertension, type 2 diabetes, and osteoarthritis is taking warfarin (target INR 2-3), bisoprolol, furosemide, ramipril, metformin, gliclazide, and co-codamol. Her INR has been unstable over the past 4 months, ranging from 1.6 to 4.2, requiring frequent monitoring. Adherence appears good. She has no symptoms of heart failure decompensation or bleeding. What medication-related factor is most likely contributing to her INR instability?
A. Interaction between warfarin and bisoprolol affecting hepatic metabolism
B. Co-codamol containing paracetamol which potentiates warfarin effect with regular use (Correct Answer)
C. Gliclazide causing variable caloric intake due to hypoglycaemia episodes affecting vitamin K intake
D. Furosemide causing dehydration and concentration changes affecting warfarin levels
E. Ramipril interaction with warfarin through effects on hepatic clearance
Explanation: ***Co-codamol containing paracetamol which potentiates warfarin effect with regular use***- Regular use of **paracetamol** (typically >2g per day for several days) can inhibit the metabolism of **vitamin K-dependent clotting factors**, leading to an elevated **INR**.- In patients with **osteoarthritis**, the chronic use of combination analgesics like **co-codamol** is a common but frequently overlooked cause of **INR instability**.*Interaction between warfarin and bisoprolol affecting hepatic metabolism*- **Bisoprolol** is a cardioselective **beta-blocker** that does not significantly induce or inhibit **CYP450 enzymes** involved in **warfarin** metabolism.- There is no clinically documented interaction between these two drugs that would result in frequent **INR fluctuations**.*Gliclazide causing variable caloric intake due to hypoglycaemia episodes affecting vitamin K intake*- While **gliclazide** can cause **hypoglycemia**, there is no evidence in the history that the patient is experiencing frequent episodes or significant **dietary changes**.- Variations in **vitamin K** intake from green leafy vegetables affect INR, but this is less likely to cause such persistent and wide ranges (1.6 to 4.2) than a direct **drug interaction**.*Furosemide causing dehydration and concentration changes affecting warfarin levels*- **Furosemide** is a **loop diuretic** that does not have a direct pharmacological interaction with **warfarin** or its metabolic pathways.- While severe **dehydration** can theoretically affect drug concentrations, it would typically present with symptoms of **renal impairment** or hypotension, which are not described here.*Ramipril interaction with warfarin through effects on hepatic clearance*- **Ramipril** is an **ACE inhibitor** primarily excreted by the kidneys and does not interfere with the **liver's** ability to process warfarin.- **ACE inhibitors** are generally considered safe for use alongside **oral anticoagulants** without the need for additional **INR monitoring**.
Question 118: During a structured medication review using the NO TEARS tool for a 73-year-old woman with rheumatoid arthritis, hypertension, type 2 diabetes, and chronic pain, you identify that she takes: methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg BD, prednisolone 5mg OD, amlodipine 5mg OD, ramipril 5mg OD, metformin 1g BD, tramadol 50mg QDS, and paracetamol 1g QDS. She reports constipation and daytime drowsiness. Which component of the NO TEARS mnemonic is most relevant to addressing her symptoms?
A. Need and indication - questioning whether prednisolone 5mg daily is still indicated
B. Open questions - exploring her understanding of why she takes each medication
C. Tests and monitoring - checking that methotrexate monitoring is up to date
D. Evidence and guidelines - reviewing whether tramadol is appropriate first-line for chronic pain
E. Adverse effects - identifying tramadol as the likely cause of constipation and drowsiness (Correct Answer)
Explanation: ***Adverse effects - identifying tramadol as the likely cause of constipation and drowsiness***- The **Adverse effects** component of the **NO TEARS** tool directly addresses identifying and managing medication side effects, which aligns perfectly with her reported symptoms. - **Tramadol**, being a weak **opioid**, commonly causes **constipation** due to reduced gut motility and **daytime drowsiness** through its central nervous system depressant effects.*Need and indication - questioning whether prednisolone 5mg daily is still indicated*- While **prednisolone** dosage requires regular review, it is unlikely to be the cause of her current **constipation** or **drowsiness** at this dose. - This component focuses on ensuring each medication still has a valid **clinical indication** and meets a specific therapeutic need.*Open questions - exploring her understanding of why she takes each medication*- **Open questions** are crucial for assessing a patient's **understanding** of their regimen and **adherence**, but they do not directly identify the underlying cause of adverse drug reactions. - This part of the review aims to gain insight into the patient's perspective and build a **patient-centered** care plan.*Tests and monitoring - checking that methotrexate monitoring is up to date*- **Methotrexate** requires routine **hematological** and **liver function** monitoring to prevent serious adverse effects, but these tests are not related to her reported symptoms. - This component ensures that medications requiring close surveillance are being safely managed through appropriate **diagnostic testing**.*Evidence and guidelines - reviewing whether tramadol is appropriate first-line for chronic pain*- While reviewing the **appropriateness** of **tramadol** for chronic pain based on guidelines is important, this step focuses on overall drug selection and efficacy rather than directly identifying present **adverse effects**. - This component assesses if the prescribed medications align with current **clinical guidelines** and best practice for her conditions.
Question 119: A 71-year-old man with COPD (post-bronchodilator FEV1 52% predicted), type 2 diabetes, hypertension, benign prostatic hyperplasia, and depression attends for annual review. Medications: metformin 1g BD, gliclazide 80mg BD, amlodipine 10mg OD, ramipril 10mg OD, tamsulosin 400mcg OD, finasteride 5mg OD, sertraline 100mg OD, tiotropium inhaler OD, salbutamol inhaler PRN, and beclometasone/formoterol 200/6 two puffs BD. He reports two COPD exacerbations in the past year requiring oral prednisolone and antibiotics. His recent HbA1c is 72 mmol/mol. What change to his treatment regimen best addresses both his COPD exacerbations and diabetes control?
A. Add azithromycin 250mg OD three times per week as prophylaxis for COPD exacerbations
B. Switch from gliclazide to empagliflozin 10mg OD for diabetes management (Correct Answer)
C. Add roflumilast 500mcg OD to reduce COPD exacerbations and improve glucose control
D. Increase beclometasone/formoterol to 400/12 two puffs BD to prevent further exacerbations
E. Add a GLP-1 receptor agonist for diabetes control and anti-inflammatory effects
Explanation: ***Switch from gliclazide to empagliflozin 10mg OD for diabetes management***- **SGLT-2 inhibitors** like empagliflozin have been shown to reduce the frequency of **acute exacerbations of COPD**, likely through anti-inflammatory and metabolic effects.- This switch addresses the patient's **poorly controlled diabetes** (HbA1c 72 mmol/mol), provides **cardiovascular and renal protection**, and avoids the **hypoglycemia risk** associated with gliclazide, especially when oral steroids are used for exacerbations.*Add azithromycin 250mg OD three times per week as prophylaxis for COPD exacerbations*- While **macrolide prophylaxis** can reduce COPD exacerbations in frequent exacerbators, it offers **no benefit** for the patient's poorly controlled **Type 2 diabetes**.- Long-term azithromycin use requires careful monitoring for risks such as **QT prolongation**, **ototoxicity**, and increased **antibiotic resistance**.*Add roflumilast 500mcg OD to reduce COPD exacerbations and improve glucose control*- **Roflumilast**, a PDE4 inhibitor, is indicated for severe COPD with chronic bronchitis and frequent exacerbations but does **not possess glucose-lowering properties**.- It is often associated with significant **gastrointestinal side effects** and **weight loss**, which might limit its tolerability and doesn't address the primary diabetes issue.*Increase beclometasone/formoterol to 400/12 two puffs BD to prevent further exacerbations*- Increasing the dose of **inhaled corticosteroids (ICS)** above recommended levels can increase the risk of local (e.g., oral candidiasis) and systemic side effects without guaranteeing a proportional additional reduction in exacerbations.- Higher ICS doses can potentially **worsen glycemic control** and increase the risk of **pneumonia** in COPD patients, which is counterproductive for this patient.*Add a GLP-1 receptor agonist for diabetes control and anti-inflammatory effects*- **GLP-1 receptor agonists** are highly effective for lowering HbA1c and promoting weight loss, but they **lack the specific evidence base** that SGLT-2 inhibitors have for reducing **COPD exacerbations**.- While they may have general anti-inflammatory effects, they are **not a recognized strategy** for managing recurrent COPD exacerbations compared to SGLT-2 inhibitors.
Question 120: You are conducting a medication review for a 76-year-old woman with osteoarthritis, osteoporosis, gastro-oesophageal reflux disease, and recurrent urinary tract infections. She takes alendronic acid 70mg weekly, calcium/vitamin D daily, omeprazole 20mg OD, paracetamol 1g QDS, and recently completed a 7-day course of trimethoprim. She mentions she has been taking ibuprofen 400mg TDS purchased over-the-counter for the past 3 months for worsening hip pain. Recent blood tests show: Hb 102 g/L (previous 128 g/L six months ago), MCV 78 fL, ferritin 18 mcg/L, eGFR 42 ml/min/1.73m² (previous 58 ml/min/1.73m² six months ago). What is the most important immediate action?
A. Arrange urgent upper gastrointestinal endoscopy for investigation of iron deficiency anaemia
B. Stop ibuprofen immediately and arrange to review in one week after checking renal function (Correct Answer)
C. Add lansoprazole 30mg OD and continue ibuprofen with gastroprotection for pain management
D. Stop omeprazole as prolonged PPI use may be causing iron malabsorption and anaemia
E. Refer to orthopaedics for consideration of hip replacement given inadequate pain control
Explanation: ***Stop ibuprofen immediately and arrange to review in one week after checking renal function***
- The patient has developed significant **acute kidney injury** (eGFR drop from 58 to 42) and **iron deficiency anaemia** (low Hb, low MCV, low ferritin) directly linked to chronic **NSAID use**.
- Stopping the causative agent (ibuprofen) is the **immediate priority** to prevent further renal deterioration and potentially life-threatening gastrointestinal blood loss.
*Arrange urgent upper gastrointestinal endoscopy for investigation of iron deficiency anaemia*
- While investigation of **iron deficiency anaemia** is essential, it is not the very first immediate action before addressing the ongoing cause of harm.
- **Urgent endoscopy** may eventually be required, but stabilization and cessation of the NSAID must occur first to prevent further acute complications.
*Add lansoprazole 30mg OD and continue ibuprofen with gastroprotection for pain management*
- Continuing **ibuprofen** is contraindicated given the established **acute kidney injury** and suspected **gastrointestinal bleeding**.
- Adding a **PPI** offers insufficient protection when clear evidence of NSAID-induced harm (anaemia, AKI) is already present, and it does not mitigate nephrotoxicity.
*Stop omeprazole as prolonged PPI use may be causing iron malabsorption and anaemia*
- A significant drop in **Hb** (128 to 102) over six months is far more consistent with **NSAID-induced gastrointestinal bleeding** than with subtle iron malabsorption from PPI use.
- Stopping **omeprazole** in a patient with GORD who is likely experiencing NSAID-related gastrointestinal irritation could worsen her reflux symptoms.
*Refer to orthopaedics for consideration of hip replacement given inadequate pain control*
- This addresses a long-term management strategy for **osteoarthritis** but completely overlooks the **acute medical emergency** of kidney injury and severe anaemia.
- The immediate focus must be on stabilizing the patient from the adverse drug reaction before considering elective surgical referrals.
